Paragon Bioservices Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Baltimore, MD USA
Total Funding:$22.9M
Industry:Biotech
Founded:1990
Lead Investor(s):NewSpring Capital, Camden Partners

Industry Ranking

State Ranking

Estimated Revenue & Financials

  • Paragon Bioservices's estimated annual revenue is currently $51.2M per year.
  • Paragon Bioservices received $5.0M in venture funding in August 2018.
  • Paragon Bioservices's estimated revenue per employee is $155,000
  • Paragon Bioservices's total funding is $22.9M.

Employee Data

  • Paragon Bioservices has 330 Employees.
  • Paragon Bioservices grew their employee count by -5% last year.
  • Paragon Bioservices currently has 89 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Intralytix
$4.7M30N/AN/AN/A
OriGene Technol...
$15.7M101-4%N/AN/A
American Gene T...
$4.7M30N/AN/AN/A
Profectus Biosc...
$3.9M25N/AN/AN/A
BioIT Solutions
$1.9M12N/AN/AN/A
BioReliance Cor...
$126.3M815N/AN/AN/A
Aziyo Biologics
$25.4M1644%N/AN/A
Osiris Therapeu...
N/A334N/AN/AN/A
Northwest Bioth...
N/A16N/AN/AN/A
Stemgent
$2.5M16N/AN/AN/A
Missing a competitor? Contribute!?
Submit

Paragon Bioservices is an industry-leading, private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon's aim is to build strong client partnerships with the world's best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic protein, and other complex biologics.

keywords:Biotechnology,Healthcare,Pharmaceuticals

330

Number of Employees

$51.2M

Revenue (est)

89

Current Jobs

-5%

Employee Growth %

$22.9M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Michele DumasManager, Sales Administration
Mark AdamsVice President Of Project Management
Ryan BehlesSr. Project ManagerEmail Available
Lauren FloccareSenior Manager, Upstream ManufacturingEmail Available
Hope MozzaniManager, Validation at Eisai, Inc
Bala MedicherlaBio-analytics ManagerEmail Available
George KuckDirector Of Manufacturing OperationsEmail Available
Ron WilsonCfo
Warren WilsonFacilities/ Manager
Nikolce GjoreskiManager, Facilities And EngineeringEmail Available

Paragon Bioservices News

09/07/2019 - Viral vector and plasmid market set for rapid growth

Just this year, Catalent bought out California-based Paragon Bioservices? and Thermo Fisher Scientific acquired Brammer Bio?, located in ...

09/08/2019 - Catalent's legacy business outshined by acquisitions

By April of 2019, Catalent had agreed to a $1.2 billion acquisition of gene therapy developer Paragon Bioservices. And most recently, the ...

04/26/2019 - Why Paragon Bioservices' $1.2B acquisition deal matters to ...

Why Paragon Bioservices' $1.2B acquisition deal matters to Baltimore ... it had agreed to acquire Paragon Bioservices in a $1.2 billion deal.

Paragon Bioservices Funding

DateAmountRoundLead InvestorsReference
2014-10-29$13.0MUndisclosedNewSpring CapitalArticle
2015-08-21$2.0MUndisclosedArticle
2018-08-14$5.0MUndisclosedArticle

Paragon Bioservices Executive Hires

DateNameTitleReference
2011-07-21Vadim KlyushnichenkoVP Preclinical Services/Process DeveloArticle
2014-10-29Peter L. BuzyCOOArticle
2015-10-01Carolyn PhillipsVP QualityArticle
2015-10-30Kevin SlySVP Marketing & Commercial StrategyArticle
2016-02-03Marco ChaconChairmanArticle
2016-02-04Peter BuzyPresidentArticle
2016-03-08William Thomas JrChief Technology OfficerArticle
2016-08-11Mark AdamsVP Project ManagementArticle
2016-09-13Peter BuzyPresident/Chief Executive OfficerArticle
2016-11-21Ruby HofmannVP Human Resources/Organizational DevelopmentArticle
2016-11-23John ConnerSVP GMP ManufacturingArticle
2017-07-21Deborah Wildvp Quality/Regulatory AffairsArticle
2018-01-26Philip WillsChief Commercial OfficerArticle
2018-06-07Gerard FleuryCFOArticle
2018-08-09Deborah WildsVice President of Quality and Regulatory AffairsArticle
2019-03-22Thomas VanCottChief Technology & Strategy OfficerArticle